AAPL294.30-2.71 (-0.91%) ▼|ABBV234.76+4.75 (+2.07%) ▲|ABT90.53+2.70 (+3.07%) ▲|ACN127.01+2.18 (+1.75%) ▲|ADBE197.43+2.53 (+1.30%) ▲|AMAT585.88-54.30 (-8.48%) ▼|AMD519.85-31.78 (-5.76%) ▼|AMGN347.01+2.29 (+0.66%) ▲|AMT179.38+2.95 (+1.67%) ▲|AMZN234.11+1.32 (+0.57%) ▲|AVGO380.15-11.98 (-3.06%) ▼|AXP337.78-0.29 (-0.09%) ▼|BA216.71-4.12 (-1.87%) ▼|BAC57.91+0.54 (+0.94%) ▲|BKNG168.94+1.17 (+0.70%) ▲|BLK1,015.33-36.41 (-3.46%) ▼|BMY55.53+0.83 (+1.52%) ▲|BNY147.29+0.85 (+0.58%) ▲|BRK-B492.81+4.12 (+0.84%) ▲|C144.97-0.70 (-0.48%) ▼|CAT984.24-38.04 (-3.72%) ▼|CL91.43+2.76 (+3.11%) ▲|CMCSA22.80+0.48 (+2.15%) ▲|COF197.81-2.89 (-1.44%) ▼|COP109.97+0.27 (+0.25%) ▲|COST957.68+6.33 (+0.67%) ▲|CRM153.42+3.30 (+2.20%) ▲|CSCO121.15-0.38 (-0.31%) ▼|CVS101.57+0.27 (+0.27%) ▲|CVX175.98+0.92 (+0.53%) ▲|DE591.94-6.65 (-1.11%) ▼|DHR178.97+0.78 (+0.44%) ▲|DIS103.53+1.08 (+1.05%) ▲|DUK125.05+1.53 (+1.24%) ▲|EMR143.14-7.07 (-4.71%) ▼|FDX317.24-11.54 (-3.51%) ▼|GD350.34+6.98 (+2.03%) ▲|GE356.47+1.35 (+0.38%) ▲|GEV1,034.98-92.61 (-8.21%) ▼|GILD125.05+0.18 (+0.14%) ▲|GM78.95-1.48 (-1.84%) ▼|GOOG346.08-2.70 (-0.77%) ▼|GOOGL346.13-3.43 (-0.98%) ▼|GS1,094.44-11.93 (-1.08%) ▼|HD324.45-2.17 (-0.66%) ▼|HON222.37-5.74 (-2.52%) ▼|IBM264.94+12.72 (+5.04%) ▲|INTC132.28-8.66 (-6.14%) ▼|INTU258.05+0.28 (+0.11%) ▲|ISRG403.18+0.23 (+0.06%) ▲|JNJ239.08+7.79 (+3.37%) ▲|JPM334.14+2.66 (+0.80%) ▲|KO80.31+0.78 (+0.98%) ▲|LIN512.26-4.45 (-0.86%) ▼|LLY1,107.08+5.00 (+0.45%) ▲|LMT503.67+10.07 (+2.04%) ▲|LOW213.54-0.86 (-0.40%) ▼|LRCX371.33-38.21 (-9.33%) ▼|MA488.07+3.98 (+0.82%) ▲|MCD271.66+1.56 (+0.58%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.63+1.36 (+1.72%) ▲|META562.20-1.65 (-0.29%) ▼|MMM161.84-1.38 (-0.85%) ▼|MO71.61+2.10 (+3.02%) ▲|MRK119.60+4.12 (+3.57%) ▲|MS226.03-1.06 (-0.47%) ▼|MSFT373.94+6.60 (+1.80%) ▲|MU1,051.77-159.61 (-13.18%) ▼|NEE86.43+0.35 (+0.41%) ▲|NFLX72.82-0.06 (-0.08%) ▼|NKE42.38-0.81 (-1.88%) ▼|NOW95.94+2.93 (+3.15%) ▲|NVDA200.04-8.61 (-4.13%) ▼|ORCL165.16-9.91 (-5.66%) ▼|PEP142.05+1.34 (+0.95%) ▲|PFE24.72-0.36 (-1.44%) ▼|PG150.86+3.18 (+2.15%) ▲|PLTR116.70-2.80 (-2.34%) ▼|PM178.69+5.52 (+3.19%) ▲|QCOM204.13-17.77 (-8.01%) ▼|RTX186.39+4.56 (+2.51%) ▲|SBUX101.05+0.90 (+0.90%) ▲|SCHW93.17+1.14 (+1.24%) ▲|SO94.93+1.50 (+1.61%) ▲|SPG216.74+2.17 (+1.01%) ▲|T22.81+0.71 (+3.21%) ▲|TMO469.35+5.34 (+1.15%) ▲|TMUS184.57+4.51 (+2.50%) ▲|TSLA381.61-23.44 (-5.79%) ▼|TXN304.36-27.92 (-8.40%) ▼|UBER69.67-1.76 (-2.46%) ▼|UNH409.25+2.57 (+0.63%) ▲|UNP258.61-1.30 (-0.50%) ▼|UPS105.83-1.41 (-1.31%) ▼|USB60.05+1.37 (+2.33%) ▲|V328.48+1.88 (+0.58%) ▲|VZ46.73+1.37 (+3.02%) ▲|WFC84.13+0.29 (+0.35%) ▲|WMT119.42+2.24 (+1.91%) ▲|XOM139.73+1.26 (+0.91%) ▲|AAPL294.30-2.71 (-0.91%) ▼|ABBV234.76+4.75 (+2.07%) ▲|ABT90.53+2.70 (+3.07%) ▲|ACN127.01+2.18 (+1.75%) ▲|ADBE197.43+2.53 (+1.30%) ▲|AMAT585.88-54.30 (-8.48%) ▼|AMD519.85-31.78 (-5.76%) ▼|AMGN347.01+2.29 (+0.66%) ▲|AMT179.38+2.95 (+1.67%) ▲|AMZN234.11+1.32 (+0.57%) ▲|AVGO380.15-11.98 (-3.06%) ▼|AXP337.78-0.29 (-0.09%) ▼|BA216.71-4.12 (-1.87%) ▼|BAC57.91+0.54 (+0.94%) ▲|BKNG168.94+1.17 (+0.70%) ▲|BLK1,015.33-36.41 (-3.46%) ▼|BMY55.53+0.83 (+1.52%) ▲|BNY147.29+0.85 (+0.58%) ▲|BRK-B492.81+4.12 (+0.84%) ▲|C144.97-0.70 (-0.48%) ▼|CAT984.24-38.04 (-3.72%) ▼|CL91.43+2.76 (+3.11%) ▲|CMCSA22.80+0.48 (+2.15%) ▲|COF197.81-2.89 (-1.44%) ▼|COP109.97+0.27 (+0.25%) ▲|COST957.68+6.33 (+0.67%) ▲|CRM153.42+3.30 (+2.20%) ▲|CSCO121.15-0.38 (-0.31%) ▼|CVS101.57+0.27 (+0.27%) ▲|CVX175.98+0.92 (+0.53%) ▲|DE591.94-6.65 (-1.11%) ▼|DHR178.97+0.78 (+0.44%) ▲|DIS103.53+1.08 (+1.05%) ▲|DUK125.05+1.53 (+1.24%) ▲|EMR143.14-7.07 (-4.71%) ▼|FDX317.24-11.54 (-3.51%) ▼|GD350.34+6.98 (+2.03%) ▲|GE356.47+1.35 (+0.38%) ▲|GEV1,034.98-92.61 (-8.21%) ▼|GILD125.05+0.18 (+0.14%) ▲|GM78.95-1.48 (-1.84%) ▼|GOOG346.08-2.70 (-0.77%) ▼|GOOGL346.13-3.43 (-0.98%) ▼|GS1,094.44-11.93 (-1.08%) ▼|HD324.45-2.17 (-0.66%) ▼|HON222.37-5.74 (-2.52%) ▼|IBM264.94+12.72 (+5.04%) ▲|INTC132.28-8.66 (-6.14%) ▼|INTU258.05+0.28 (+0.11%) ▲|ISRG403.18+0.23 (+0.06%) ▲|JNJ239.08+7.79 (+3.37%) ▲|JPM334.14+2.66 (+0.80%) ▲|KO80.31+0.78 (+0.98%) ▲|LIN512.26-4.45 (-0.86%) ▼|LLY1,107.08+5.00 (+0.45%) ▲|LMT503.67+10.07 (+2.04%) ▲|LOW213.54-0.86 (-0.40%) ▼|LRCX371.33-38.21 (-9.33%) ▼|MA488.07+3.98 (+0.82%) ▲|MCD271.66+1.56 (+0.58%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.63+1.36 (+1.72%) ▲|META562.20-1.65 (-0.29%) ▼|MMM161.84-1.38 (-0.85%) ▼|MO71.61+2.10 (+3.02%) ▲|MRK119.60+4.12 (+3.57%) ▲|MS226.03-1.06 (-0.47%) ▼|MSFT373.94+6.60 (+1.80%) ▲|MU1,051.77-159.61 (-13.18%) ▼|NEE86.43+0.35 (+0.41%) ▲|NFLX72.82-0.06 (-0.08%) ▼|NKE42.38-0.81 (-1.88%) ▼|NOW95.94+2.93 (+3.15%) ▲|NVDA200.04-8.61 (-4.13%) ▼|ORCL165.16-9.91 (-5.66%) ▼|PEP142.05+1.34 (+0.95%) ▲|PFE24.72-0.36 (-1.44%) ▼|PG150.86+3.18 (+2.15%) ▲|PLTR116.70-2.80 (-2.34%) ▼|PM178.69+5.52 (+3.19%) ▲|QCOM204.13-17.77 (-8.01%) ▼|RTX186.39+4.56 (+2.51%) ▲|SBUX101.05+0.90 (+0.90%) ▲|SCHW93.17+1.14 (+1.24%) ▲|SO94.93+1.50 (+1.61%) ▲|SPG216.74+2.17 (+1.01%) ▲|T22.81+0.71 (+3.21%) ▲|TMO469.35+5.34 (+1.15%) ▲|TMUS184.57+4.51 (+2.50%) ▲|TSLA381.61-23.44 (-5.79%) ▼|TXN304.36-27.92 (-8.40%) ▼|UBER69.67-1.76 (-2.46%) ▼|UNH409.25+2.57 (+0.63%) ▲|UNP258.61-1.30 (-0.50%) ▼|UPS105.83-1.41 (-1.31%) ▼|USB60.05+1.37 (+2.33%) ▲|V328.48+1.88 (+0.58%) ▲|VZ46.73+1.37 (+3.02%) ▲|WFC84.13+0.29 (+0.35%) ▲|WMT119.42+2.24 (+1.91%) ▲|XOM139.73+1.26 (+0.91%) ▲|
18.5 C
New York
Wednesday, June 24, 2026

Tag: patients

newssourceFORcompanyinformationcontent1marketreleases

Shilpa Medicare’s NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty...

GERON (GERN) ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf of long-term stockholders following a class action complaint that was filed against Geron on March 14, 2025 with a Class Period from February 28, 2024 to February 25, 2025. Our investigation concerns whether the board of directors of Geron have breached their fiduciary duties to the company.

Golden State Dermatology Grows to 10 Southern California Locations with Acquisition of Two-Location Practice

MONTCLAIR, Calif., Aug. 13, 2025 /PRNewswire/ -- Golden State Dermatology (GSD) is pleased to announce a new partnership with Dr. Laurie Woll's practice, with locations...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a...

Applied Therapeutics Reports Second Quarter 2025 Financial Results

- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD

Solventum Announces Launch of Secondary Offering of Common Stock

ST. PAUL, Minn., Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV, "Company" or "Solventum") today announced the launch of a secondary offering (the "Offering")...

HopeAI Showcases AI-Powered Synthetic Data to Speed Up Cancer Drug Trials at ASCO 2025

NEW YORK, Aug. 13, 2025 /PRNewswire/ -- HopeAI , a Mayo Clinic Platform Accelerate company, is advancing how cancer clinical trials are designed and...

Elevating Clinical Excellence: TLCx Appoints Dr Ries as Chief Medical Officer

CEDAR RAPIDS, Iowa, Aug. 13, 2025 /PRNewswire/ -- TLCx is taking a significant step toward its long-term vision of transforming the healthcare patient experience. This...

Erdem Hospital Performs First-of-Its-Kind Spinal Revision Surgery

Erdem Hospital’s first spinal revision surgery restores mobility to an Italian patient, ending years of paralysis and enabling her to walk again.

Whole Genome Sequencing Market to Reach New Heights by 2030

"With cutting-edge advances in next-generation sequencing and growing interest in personalized medicine, whole genome sequencing is set to transform disease diagnosis and treatment, driving...

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability.

MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States

MediPharm Labs holds unique US Food and Drug Administration (FDA) site registration in relation to the manufacturing and release of pharmaceutical cannabis products.  MediPharm...

On World Organ Donation Day KFSHRC Announces 10 Kidney Exchange Transplants Completed in 48 Hours

RIYADH, Saudi Arabia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) successfully performed 10 kidney exchange transplants over two consecutive days, setting a global record for the highest number of such procedures conducted within a two-day span at a single center, coinciding with World Organ Donation Day on August 13. This milestone reinforces KFSHRC’s position as a global leader in organ transplantation.

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatients

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers